ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20^th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. Details of the presentations are as follows:

IDDST 2024. Osaka, Japan. May 22-24, 2024.

• Title: Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema
  Presenter: Anne Lesage, Ph.D.
  Format: Oral Presentation
  Date, time: Wednesday, May 22, 10:55-11:20 a.m. JST (Tuesday, May 21, 9:55-10:20 p.m. EDT)
  

EAC 2024. Palm Beach, Florida, U.S. May 30-June 2, 2024.

• Title: Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema
  Presenter: Henry Li, M.D., Ph.D.
  Format: Poster Presentation
  Date, time: Saturday, June 1, 9:45-11:00 a.m. EDT
  

EAACI Congress 2024. Valencia, Spain. May 31-June 3, 2024.

• Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Oral Presentation
  Date, time: Saturday, June 1, 17:21 CEST (11:21 a.m. EDT)
• Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
  Presenter: Anna Valerieva, M.D., Ph.D.
  Format: Oral Presentation
  Date, time: Saturday, June 1, 17:33 CEST (11:33 a.m. EDT)
• Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
  Presenter: Marcus Maurer, M.D.
  Format: Poster (Flash Talk) Presentation
  Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
• Title: Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks
  Presenter: Laurence Bouillet, M.D., Ph.D.
  Format: Poster (Flash Talk) Presentation
  Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
• Title: Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat
  Presenter: Anne Lesage, Ph.D.
  Format: Poster (Flash Talk) Presentation
  Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
• Title: Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases
  Presenter: Evangelia Pardali, Ph.D.
  Format: Poster (Flash Talk) Presentation
  Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)

Abstracts from the EAACI Congress will be published in Allergy (the European Journal of Allergy and Clinical Immunology) after the Congress. The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.